Peter Altman Biography and Net Worth

CEO of BioCardia

Dr. Altman has served as our President and CEO since 2002. He was CEO (1999 to 2003) and board member (1999 to 2014) of CareDx (NASDAQ: CDNA), a developer of a gene-based diagnostics for cardiac and other organ transplantation. He was CEO for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He has extensive experience in life science research and product development, is named inventor in 45 U.S. patents, and has authored 40 scientific publications. Dr. Altman currently serves as a director on the board of Oncocyclist Biotech. He received his Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his Master of Science and Bachelor of Science in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman has been elected Fellow of the American Heart Association.

What is Peter Altman's net worth?: The estimated net worth of Peter Altman is at least $222,248.41 as of November 15th, 2024. Dr. Altman owns 105,331 shares of BioCardia stock worth more than $222,248 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Altman may own. Additionally, Dr. Altman receives an annual salary of $515,510.00 as CEO at BioCardia. Learn More about Peter Altman's net worth.
How old is Peter Altman?: Dr. Altman is currently 57 years old. There are 2 older executives and no younger executives at BioCardia. Learn More on Peter Altman's age.
What is Peter Altman's salary?: As the CEO of BioCardia, Inc., Dr. Altman earns $515,510.00 per year. Learn More on Peter Altman's salary.
How do I contact Peter Altman?: The corporate mailing address for Dr. Altman and other BioCardia executives is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. BioCardia can also be reached via phone at (650) 226-0120 and via email at [email protected]. Learn More on Peter Altman's contact information.
Has Peter Altman been buying or selling shares of BioCardia?: Over the course of the past ninety days, Peter Altman has bought $2,524.50 in BioCardia stock. Most recently, on Friday, November 15th, Peter Altman bought 1,350 shares of BioCardia stock. The stock was acquired at an average cost of $1.87 per share, with a total value of $2,524.50. Following the completion of the transaction, the chief executive officer now directly owns 105,331 shares of the company's stock, valued at $196,968.97. Learn More on Peter Altman's trading history.
Are insiders buying or selling shares of BioCardia?: In the last twelve months, BioCardia insiders bought shares 9 times. They purchased a total of 11,273 shares worth more than $61,739.50. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 8,653 shares worth more than $55,811.85. The most recent insider tranaction occured on November, 15th when CEO Peter Altman bought 1,350 shares worth more than $2,524.50. Insiders at BioCardia own 20.0% of the company. Learn More about insider trades at BioCardia.
Information on this page was last updated on 11/15/2024.

Peter Altman Insider Trading History at BioCardia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2024	Buy	1,350	$1.87	$2,524.50	105,331
7/1/2024	Buy	300	$3.05	$915.00	39,745
6/28/2024	Buy	200	$2.99	$598.00	39,445
6/21/2024	Buy	500	$3.29	$1,645.00	39,245
6/14/2024	Buy	500	$3.52	$1,760.00	38,745
6/10/2024	Buy	1,000	$3.36	$3,360.00	38,245
4/19/2024	Buy	183	$5.55	$1,015.65	37,246
3/28/2024	Buy	33	$5.85	$193.05	37,063
2/13/2024	Buy	7,207	$6.90	$49,728.30	37,029
5/26/2023	Buy	413	$24.00	$9,912.00	31,282
1/11/2023	Buy	6	$28.05	$168.30	23,581
9/23/2022	Buy	93	$28.05	$2,608.65	21,896
9/21/2022	Buy	183	$28.80	$5,270.40	21,596
6/10/2022	Buy	300	$21.90	$6,570.00	21,413
5/13/2022	Buy	179	$20.70	$3,705.30	23,209
5/11/2022	Buy	66	$19.50	$1,287.00	22,276
4/28/2022	Buy	153	$23.85	$3,649.05	22,029
4/18/2022	Buy	900	$20.85	$18,765.00	21,876
11/18/2021	Buy	333	$33.00	$10,989.00
8/17/2021	Buy	233	$44.10	$10,275.30	15,527
12/1/2020	Buy	66	$37.35	$2,465.10	13,546
11/27/2020	Buy	213	$35.55	$7,572.15	13,546
11/12/2020	Buy	133	$31.05	$4,129.65	13,726
11/10/2020	Buy	166	$29.70	$4,930.20	13,593
3/24/2020	Buy	80	$43.50	$3,480.00	11,460
3/19/2020	Buy	26	$44.25	$1,150.50	11,380
3/12/2020	Buy	226	$47.25	$10,678.50	11,120
6/5/2019	Buy	133	$15.30	$2,034.90
5/28/2019	Buy	13	$19.20	$249.60
5/17/2019	Buy	140	$17.25	$2,415.00
5/1/2019	Buy	733	$16.20	$11,874.60
2/13/2019	Buy	3	$23.85	$71.55
11/16/2018	Buy	426	$35.10	$14,952.60
11/13/2018	Buy	260	$32.40	$8,424.00
11/9/2018	Buy	33	$37.50	$1,237.50
11/2/2018	Buy	26	$37.80	$982.80
10/30/2018	Buy	20	$38.25	$765.00
10/26/2018	Buy	256	$35.40	$9,062.40
9/20/2018	Buy	73	$26.10	$1,905.30
9/18/2018	Buy	46	$23.85	$1,097.10
9/12/2018	Buy	106	$20.55	$2,178.30
9/5/2018	Buy	333	$19.95	$6,643.35
8/27/2018	Buy	100	$21.90	$2,190.00
6/11/2018	Buy	200	$21.75	$4,350.00
4/18/2018	Buy	66	$21.75	$1,435.50
3/20/2018	Buy	333	$30.45	$10,139.85

Peter Altman Buying and Selling Activity at BioCardia

BioCardia Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Today's Range

Now: $2.14

$1.98

$2.15

50 Day Range

MA: $2.55

$1.85

$3.12

2 Week Range

Now: $2.14

$1.84

$10.95

Volume

37,321 shs

Average Volume

292,761 shs

Market Capitalization

$4.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

“This Changes Everything” - Trump Hands Millions Massive IRS Gift

From Colonial Metals | Ad

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!

Peter Altman Biography and Net Worth

What is Peter Altman's net worth?

How old is Peter Altman?

What is Peter Altman's salary?

How do I contact Peter Altman?

Has Peter Altman been buying or selling shares of BioCardia?

Are insiders buying or selling shares of BioCardia?